Prof. Eldad Zacksenhaus

University Health Network, Canada

Email: [email protected]

Qualifications

1990 Ph.D., University of Toronto, microbiology

1980 B.Sc., Tel-Aviv University, chemistry

Publications (selected)

1. Wang, D. Y., Jiang, Z., Ben-David, Y., et al. (2026). TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression. British Journal of Cancer. Advance online publication.
2. Yang, Z. Y., Hong, J. K., Liu, W. L., et al. (2026). Yuxingcao formula suppresses acute erythroleukemia through inhibition of AKT1 and FLI1. Fitoterapia, 189, Article 107079.
3. Liu, J. C., Granieri, L., Shrestha, M., et al. (2025). Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer (vol 23, pg 112, 2018). Cell Reports, 44(11), Article 116560.
4. Jiang, Z., Baechler, B. L., Li, H. Q., et al. (2025). The tumor suppressor pRb and its relative p130 are required to maintain murine adult skeletal muscle homeostasis. Oncogene, 44(30), 2662–2674.
5. Hong, J. K., Yang, Z. Y., Gao, J., et al. (2025). Vitamin D3 and its active form calcitriol suppress erythroleukemia through upregulation of CHAC1 and downregulation of NOTCH1. Medical Oncology, 42(5), Article 138.
6. Jiang, Z., Allkanjari, M. S., Chung, P. E. D., et al. (2025). Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities. Cancers, 17(5), Article 720.
7. Hu, M. T., Yu, K. L., Wang, C. L., et al. (2025). FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression. Journal of Inflammation Research, 18, 4213–4231.
8. Yu, K. L., Tang, Y., Wang, C. L., et al. (2024). The Astragalus Membranaceus Herb Attenuates Leukemia by Inhibiting the FLI1 Oncogene and Enhancing Anti-Tumor Immunity. International Journal of Molecular Sciences, 25(24), Article 13426.
9. Ran, X. J., Hu, A. L., Kuang, Y., et al. (2024). UM171 suppresses breast cancer progression by inducing KLF2. Breast Cancer Research and Treatment, 207(2), 405–415.
10. Wang, C. L., Hu, M. T., Yu, K. L., et al. (2024). An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation. Molecular Medicine Reports, 29(6), Article 107.
11. Wang, J., Wang, C. L., Hu, A. L., et al. (2024). FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression. BMC Cancer, 24(1), Article 326.
12. Jiang, Z., Ju, Y. J., Ali, A., et al. (2023). Thinking (Metastasis) outside the (Primary Tumor) Box. Cancers, 15(22), Article 5315.
13. Jiang, Z., Ju, Y. J., Ali, A., et al. (2023). Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer. Nature Communications, 14(1).
14. Shrestha, M., Wang, D. Y., Ben-David, Y., et al. (2023). CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. Oncogenesis, 12(1), Article 29.
15. Gao, J., Hu, J. F., Yu, F., et al. (2023). Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling. BMC Cancer, 23(1), Article 306.
16. Idriss, S., Hallal, M., El-Kurdi, A., et al. (2023). A temporal in vivo catalog of chromatin accessibility and expression profiles in pineoblastoma reveals a prevalent role for repressor elements. Genome Research, 33(2), 269–282.
17. Hu, J. F., Gao, J., Wang, C. L., et al. (2023). FLI1 Regulates Histamine Decarboxylase Expression to Control Inflammation Signaling and Leukemia Progression. Journal of Inflammation Research, 16, 2007–2020.
18. Sheng, D. M., Chen, B. L., Wang, C. L., et al. (2022). FLI1 accelerates leukemogenesis through transcriptional regulation of pyruvate kinase-L/R and other glycolytic genes. Medical Oncology, 40(2), Article 69.
19. Hu, A. L., Gao, J., Varier, K. M., et al. (2022). UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression. Cell Death Discovery, 8(1), Article 448.
20. Xiao, X., Chung, P. E. D., Xu, M., et al. (2022). A racemosin B derivative, C25, suppresses breast cancer growth via lysosomal membrane permeabilization and inhibition of autophagic flux. Biochemical Pharmacology, 201, Article 115060.

Profile Details
https://lmp.utoronto.ca/faculty/eldad-zacksenhaus
https://scholar.google.com/citations?user=ac8CXNcAAAAJ&hl=en
https://www.researchgate.net/scientific-contributions/Eldad-Zacksenhaus-39425510

WOS ResearcherID: HSC-7108-2023